



RAPID RISK ASSESSMENT

Risk of measles transmission in the EU/EEA

20 March 2018

Main conclusions and options for response

Measles cases in the EU/EEA are principally occurring in unvaccinated populations, both adults and children. Large outbreaks with fatalities are ongoing in countries that had eliminated or interrupted endemic transmission.

Vaccination coverage and the distribution of outbreaks both show strong spatial heterogeneity across and within countries. Even if a country has an overall coverage of 95%, there is still the potential for outbreaks in subnational zones or communities with low coverage (i.e. they may be delimited either geographically or socio-demographically).

The high proportion of cases with unknown vaccination status among young adults (13% among 25-29 years old), highlights the importance of registration tools, in particular electronic registers to document the vaccination status of individuals. Such registers have the important potential of providing timely vaccination coverage data even at subnational level, something lacking in a number of Member States.

Some countries have seen an increasing proportion of cases among adults, prompting the need to consider catch-up campaigns. Member states are encouraged to identify existing immunity gaps in specific population groups to facilitate supplementary immunization activities (SIAs).

Lastly, the frequent occurrence of measles among healthcare workers in several EU/EEA countries is a reason of concern and Member States may consider specific interventions in this regard. Ensuring that all healthcare workers are immune to measles, with proof/documentation of immunity or immunization, should be considered as a condition of enrolment into training and employment.

Given the current extent of measles circulation in the EU/EEA, the trend in recent years, and that vaccination coverage for the first and second dose is suboptimal, there is a high risk of continued measles transmission with mutual exportation and importation between EU/EEA Member States and third countries.

Source and date of request

ECDC Internal Decision, 23 February 2018.

Disclaimer: This preliminary version the Rapid Risk Assessment is circulated through the Early Warning and Response System and sent to national focal points in advance of publication on the ECDC website. The document should not be circulated beyond the intended recipients and readers should be aware that the public version may differ from this version as a result of editing and internal quality control.

Suggested citation: European Centre for Disease Prevention and Control. [Risk of measles transmission in the EU/EEA] – [14/3/2018], Stockholm, 2018.

Public health issue

Risk of further spread and sustained transmission of measles in EU/EEA countries related to ongoing outbreaks and insufficient vaccination coverage.

Consulted experts

ECDC experts (in alphabetical order): Tarik Derrough, Helen Johnson, Grazina Mirinaviciute, Olivia Aya Nakitanda, Emmanuel Robesyn, Emmanouela Sdona

External experts consulted (in alphabetical order): Antonietta Fila, Istituto Superiore di Sanità, Italy; Theano Georgakopoulou, Hellenic Center for Disease Control & Prevention; Daniel Lévy-Bruhl, Santé publique France; Maria Cristina Rota, Istituto Superiore di Sanità, Italy.

Experts from the World Health Organization (WHO) Regional Office for Europe contributed to this risk assessment. Although experts from WHO reviewed the risk assessment, the views expressed in this document do not necessarily represent the views of WHO. All experts have submitted declarations of interest and a review of these declarations did not reveal any conflicts of interest.

Disease background information

Measles is an acute illness caused by *morbillivirus*. The disease is transmitted via airborne respiratory droplets, or by direct contact with nasal and throat secretions of infected individuals. Measles is highly infectious and it is estimated that 90% of non-immune people exposed to an infectious individual will contract the disease.

The main symptoms are fever, rash, cough, runny nose and inflammation of the eye. The first symptoms appear on average 10 days after exposure, but with a range of 7–21 days from exposure to onset of fever. A rash usually appears four days after the start of the first symptoms, and patients are contagious from about 4 days before until 4 days after eruption of the rash.

Complications can include pneumonia, encephalitis, otitis media, diarrhoea, laryngotracheo-bronchitis and secondary bacterial infections. Subacute sclerosing panencephalitis (SSPE), a severe but rare and slowly progressing degenerative disease of the central nervous system, characterised by behavioural and intellectual deterioration and seizures may develop six to eight years after primary infection.

Infants, immunocompromised individuals and adults are at higher risk of complications, severe disease and death following measles infection.


Measles frequently results in widespread outbreaks, mainly among unvaccinated individuals. The disease is preventable by vaccination, which provides lifelong immunity in most recipients. Vaccine uptake of at least 95% with two doses of measles containing vaccine is considered necessary to ensure the level of immunity in the population required to interrupt disease circulation and achieve elimination.

For a more complete background of the disease and its epidemiology in the EU, please refer to the ECDC health topic page on measles [1].

Event background information

Between 1 January 2017 and 31 December 2017, EU/EEA Member States reported 14 600 cases of measles to the European surveillance system (TESSy). The total number of cases was more than triple the number of reported cases in 2016 (4 642) and 2015 (4 000). Further, 2 239 cases have been reported by the Romanian Institute of Public Health and are not yet submitted in TESSy [2].

Figure 1. Number of monthly reported measles cases, EU/EEA countries *, 1999 – 2018 (n = 196043).



Source: TESSy as of 28th February 2018

* Two peaks of measles in Romania in 2005 (n = 5647) and in 2006 (n = 3196) are not included in the graph as Romania accessed the EU in 2007.


More than 75% of all reported cases in 2017 were recorded in the first half of the year, with the highest numbers in the months of March (2 802), April (2 474) and May (2 244). Following a sharp decline in the number of cases in the summer months, a steady increase was observed towards the end of the year (Figure 1).

The number of cases by country and the subnational notification rate per million population per country for the calendar year 2017 are presented in Figures 2 (left panel) and 3 respectively.

For January 2018, the number of cases (n=1 073) by country is presented in Figure 2 (right panel). All but one (Malta) EU/EEA countries reported measles cases in 2017 and January 2018.


In 2017, most cases were reported by Romania (5 608), Italy (5 098), Greece (967), Germany (929) and France (518), accounting, respectively, for 38%, 35%, 7%, 6% and 4% of all cases reported by EU/EEA countries. Since the end of 2017, Greece and France reported a notable increase in cases.

Figure 2. Distribution of measles cases by country, EU/EEA, 1 January – 31 December 2017 (n=14 600) (left panel) and January 2018 (n=1 073) (right panel)



The spread of measles cases is not only heterogeneous between countries, but also within countries (Figure 3).


Figure 3. Subnational distribution of measles cases per million population by place of notification*, EU/EEA, 1 January 2017 – 31 December 2017



*For Denmark, subnational notification rates are based on place of residence. For Belgium, Cyprus, Finland, Iceland, Luxembourg and Norway, the notification rates by country are presented, as reported in TESSy.

In 2017, 37 deaths due to measles were reported across the EU/EEA; with 26 in Romania, four in Italy, two in Greece, and one each in Bulgaria, France, Germany, Portugal and Spain [3] (Figure 4). A further 7 deaths have been reported in 2018; with 3 in Romania, 2 in Italy, one each in Greece and France [4].

Figure 4. Distribution of measles deaths by country, EU/EEA, 1 January 2017–31 December 2017 (n=37)



In 2017, among 13 716 cases with known importation status, 12 160 (89%) were reported to be endemic, 1 173 (9%) import-related and 383 (3%) imported.


Of 14 600 cases with known age, 5 284 (37%) were children less than five years of age, while 6 656 (45%) were aged 15 years or older. The highest incidence was reported in children below one year of age (365.9 cases per million), followed by children from 1 to 4 years of age (164.4 cases per million).

Among 13 753 cases with known vaccination status, 87% were unvaccinated, 8% were vaccinated with one dose of measles containing vaccine, 3% were vaccinated with two or more doses, and 2% were vaccinated with an unknown number of doses. Of all cases, 6% had an unknown vaccination status. The proportion of cases with unknown vaccination status was highest in adults aged 25-29 years (13%).

The proportion of unvaccinated cases among the age groups targeted for vaccination ranged from 72% (25-29 year olds) to 86% (1-4 year olds). Among cases below one year of age, the proportion of unvaccinated cases was 96% as most vaccination programmes only target vaccination from one year of age. Infants below the age of one year are particularly vulnerable to complications of measles and are best protected by herd immunity, which is achieved when population coverage for the second dose of a measles containing vaccine is at least 95%.

Measles continues to spread across Europe as the vaccination coverage in many EU/EEA countries is suboptimal. The latest available data on national vaccination coverage for the first and second doses of measles containing vaccine are presented in Figure 5 [5]. The vaccination coverage in 2016 for the second dose of measles containing vaccine was below 95% in 22 of 29 EU/EEA countries with data (Figure 5). If the elimination goal is to be reached, vaccination coverage needs to increase in a number of countries as, operationally, the vaccination coverage target for the second dose is at least 95% to interrupt measles circulation.

Figure 5. Vaccination coverage for the first (left panel) and second (right panel) doses of measles containing vaccine by country, EU/EEA, 2016, WHO



Since the beginning of 2018, large outbreaks of measles continue to be reported from Greece (1131) [6], Romania (757) [2], France (429) [7], Italy (168) and Portugal (145) [8]. Smaller outbreaks of measles were also reported in other EU/EEA countries: Belgium (5), Czech Republic (23) [9], Germany (33) [10], Ireland (44) [11], Latvia (9) [12], Norway (4) [13], Poland (17) and Sweden (28) [14].

Healthcare workers

In the EU/EEA, several measles outbreaks reported in 2017 and at the start of 2018 involved infected healthcare workers (HCW), including Belgium (35 cases in HCW) [15], Czech Republic (20 cases in HCW) [16], Italy (315 cases in HCW) [17], Greece (67 cases in HCW) [18], and Norway (2 cases in HCW) [13]. Transmission in healthcare settings has been seen also in countries with high vaccination coverage, e.g. Sweden (1 case in HCW) [19] and Portugal (28 cases in HCW) [20]. As healthcare workers are prone to be in contact both with measles cases and with susceptible infants and immunocompromised patients, they have a large potential to amplify measles transmission. Some countries, e.g. recently Denmark [21,22] and Sweden (Göteborg) [23], have taken specific measures to facilitate access to vaccination for unimmunized adults and for healthcare workers.

Romania

ECDC has previously published a Rapid Risk Assessment on the outbreak in Romania [24]. According to the Romanian National Institute of Public Health (INSPI), 11 123 confirmed cases of measles and 40 deaths had been registered, as of 9 March 2018 since the beginning of the outbreak in early 2016 [2]. The outbreak reached a peak with 1315 cases in May 2017 [2]. The case count then dropped from about 300 per week between April and June, to 50 per week since the summer of 2017. The main circulating genotype in Romania was B3 and young children were the most affected, with 55% of the 5 608 cases reported to TESSy in 2017 aged less than 5 years.

Despite the decreasing number of cases being reported, Romania still experiences large case counts. In the first two months of 2018, 757 confirmed cases of measles had been reported, including three deaths [2].

The vaccination coverage estimates for measles containing vaccine in Romania submitted to the WHO for 2016 were 86% and 76% for the first and second doses respectively [5].

Italy

Since January 2017, the monthly case count in Italy increased through late winter to early spring, peaking in March 2017 with 943 cases reported. For 2017, Italy reported a total of 5 098 cases and 4 deaths. Adults were the most affected, with 68% of reported cases aged above 20 years. However, the highest incidence was recorded in infants below one year of age. In 2017, 88% (4 146) of cases with known vaccination status were reported to be unvaccinated and 7% were vaccinated with only one dose. The main circulating genotypes reported were B3 and D8.

In January 2018, Italy reported 168 cases of measles, including 2 deaths. Cases are reported from 12 regions of Italy with the majority being reported from Sicily, Lazio, Calabria and Liguria regions. The median age of the cases is 25 years (range 2 days to 62 years) and 15 cases were children under one year of age. Of all reported cases, 93% were unvaccinated or have received one dose of measles containing vaccine.

The vaccination coverage estimates for measles containing vaccine in Italy submitted to the WHO for 2016 were 85% and 83% for the first and second doses respectively [5]. In 2016, 87% of 2 year-olds had received one dose and 82% of 5-6 year olds had received 2 doses of measles containing vaccine [25].

France

In 2017, France reported an increasing number of cases with an early peak in May (114 cases), followed by a sharp decline with fewer cases in the summer and autumn. In December 2017, France reported a new increase with 65 cases, compared to 13 and 11 cases in October and November respectively. France reported in 2017, a total of 518 cases, including one death. Adults and children were equally affected. In 2017, genotype D8 and B3 were circulating, whereas in 2018, so far the circulating genotype is D8.

Since 6th November 2017, and as of 12th March 2018, 913 cases have been reported, with one death in February. Cases were reported across almost all regions in the last weeks, with half of all cases from the region Nouvelle Aquitaine. Of 201 hospitalized patients, 78 had complications and 9 required resuscitative care. Almost 90% of cases with known vaccination status occurred in persons who were incompletely vaccinated or unvaccinated [26].

The vaccination coverage estimates for measles containing vaccine in France submitted to the WHO for 2016 were 90% and 79% for the first and second doses respectively [5].

Figure 6: Distribution of measles cases by week of onset, France, 2017-2018.





Figure 7. Distribution of measles cases by week of onset, Greece, 2017-2018

Source: HCDCP as of 15th March

Note: Cases per week are calculated by subtracting total number of cases published in the weekly updates of the HCDCP from the total number of cases published in the previous update.

As of 4th March, most cases (64%) were in Roma population followed by non-minority Greek nationals (25%). Of the total, 69% (n=1373) were children aged up to 14 years of age. Adults aged 20 years and older constituted 31% (n=503) of the total reported cases, mainly 25–44 years old. The outbreak mainly affects Southern Greece and especially the regions of Dytiki Ellada, Peloponnese and Attica. Molecular characterization of the circulating measles virus in Greece identified B3 genotype [18].

According to annual coverage report submitted to WHO, estimated national immunization coverage for measles containing vaccine in 2016 were 97% and 83% for the first and second doses respectively [5]. Despite this high estimated national coverage, reliable estimates of Roma vaccination coverage are limited. According to a recent study reporting a vaccination coverage survey of Roma children at national level in Greece, coverage for all vaccines was found to be very low [28].

Portugal

A recent measles outbreak in the Northern Region of Portugal, epidemiologically linked to the outbreak in France, was reported to include 145 suspected cases of which 53 have been confirmed. Twenty-eight of the confirmed cases are healthcare workers [8,20]. Portugal reported 34 cases of measles between February and May 2017. No cases were reported for 2016, and for the period between June 2017 and January 2018.

The vaccination coverage estimates for measles containing vaccine in Portugal submitted to the WHO for 2016 were 98% and 95% for the first and second doses respectively [5].

Neighbouring countries

Ukraine

In other European countries outside the EU, the largest outbreak of measles continues in Ukraine [29] with 6 484 cases in 2018 as of 6 March, including seven deaths (five children and two adults). Among the cases, 66% were children and 34% adults. Most of the cases were reported from Ivano-Frankivsk, Zakarpattia, Odesa, Chernivtsi and Lviv regions. In 2017, Ukraine reported 4 782 cases and seven deaths (four children and three adults). Vaccination coverage with measles containing vaccines in Ukraine in 2017 has doubled compared to 2016, with 93.3% of children under one year of age and 90.7% of six year-olds vaccinated.

Balkan region

Outbreaks of measles have been reported from the Balkan region in 2018. As of 12 March, 3 442 measles cases, of which 1 778 laboratory confirmed, were detected across the **Republic of Serbia and from Kosovo***. The majority of cases are below five years of age and over 30 years of age. The majority of cases in the Republic of Serbia were reported from Belgrade. Of all the cases, 95% were unvaccinated or had unknown vaccination status. Thirty two per cent were hospitalised and 383 cases developed neurological or pulmonary complications. Since the beginning of the outbreak, nine people died of pulmonary measles complications, including two four- and two-year-old children. Between 23 October 2017 and 12 March 2018, Kosovo* and Metohija reported 334 cases of measles [30].

According to the annual Joint Reporting form submitted to WHO, the first dose of measles containing vaccine in Serbia is given to 12 months old children and a second dose at the age of 7 years [31]. Vaccination coverage for first and second dose of measles containing vaccine has been around or below 90% for several years, with 82% for the first and 90% for the second dose in 2016 [5].

Albania reported the first case in January 2018, and as of 23 February 162 confirmed cases were detected in the country [32].

The **Former Yugoslav Republic of Macedonia** reported 19 cases of measles at the end of 2017 [33], and **Bosnia and Herzegovina** had experienced an outbreak of measles in 2014 and 2015 with 3000 and 1677 cases, respectively [34].

ECDC threat assessment for the EU

Measles cases in the EU/EEA are principally occurring in unvaccinated populations, affecting both adults and children. Large outbreaks with fatalities are ongoing in countries that had eliminated or interrupted endemic transmission as outlined below.

The progress towards elimination of measles in the European Region of WHO is assessed by The European Regional Verification Commission for Measles and Rubella Elimination (RVC). At the sixth meeting of the RVC for Measles and Rubella in June 2017, of 53 countries in the WHO European Region, 33 (22 of which are in EU/EEA) were declared to have reached the elimination goal for measles. Additionally, four EU/EEA countries were assessed to have interrupted endemic transmission for less than 36 months, meaning they are on their way to achieving the elimination goal. However, four EU/EEA countries were judged to still have endemic transmission of measles: Belgium, France, Italy and Romania (Table 2)[35].

The RVC assesses the status of countries based on a number of components: the epidemiological situation in the last 36 months, the molecular epidemiology, the surveillance performance, the population immunity, and the sustainability of the national immunization programme [36]. The information regarding these components are submitted by National Verification Committees, who play an important role within the Member States. The RVC will next convene in June 2018 and, based on the current epidemiological situation, we can expect the status of some countries to change and some may have their elimination status revised.

* This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ opinion on the Kosovo declaration of independence.

Table 2: Elimination status of EU/EEA member states, based on the 2016 data review by the Regional Verification Commission meeting in June 2017.

Elimination status	Country
EU/EEA Member States judged to have eliminated the disease (≥ 36 months without endemic transmission)	Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Greece, Hungary, Iceland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, the United Kingdom
EU/EEA Member States judged to have interrupted endemic transmission for 24 months	Ireland
EU/EEA Member States judged to have interrupted endemic transmission for 12 months	Austria, Germany, Poland
EU/EEA MS judged to have endemic transmission	Belgium, France, Italy, Romania

Vaccination coverage and the distribution of outbreaks both show strong spatial heterogeneity across and within countries. Even if a country has an overall coverage of 95%, there is still the potential for outbreaks in subnational zones or communities with low coverage (i.e. they may be delimited either geographically or socio-demographically).

The high proportion of cases with unknown vaccination status among young adults (13% among 25-29 years old), highlights the importance of registration tools, in particular electronic registers to document vaccination status of individuals. Such registers have the important potential of providing timely vaccination coverage data even at subnational level, something lacking in a number of Member States.

Some countries have seen an increasing proportion of cases among adults, prompting the need to consider catch-up campaigns. Member states are encouraged to identify existing immunity gaps in specific population groups to facilitate supplementary immunization activities (SIAs).

Lastly, the frequent occurrence of measles among healthcare workers in several EU/EEA countries is a reason of concern and Member States may consider specific interventions in this regard. Ensuring that all healthcare workers are immune to measles, with proof/documentation of immunity or immunization, should be considered as a condition of enrolment into training and employment [37].

Main conclusions and options for response

Immunisation is the only effective preventive measure against acquiring measles. All countries in the EU/EEA have measles vaccination policies in place with two doses using an MMR vaccine. Catch-up programmes for individuals having missed vaccination or being too old to have been targeted by routine programmes exist in a number of countries. In response to ongoing outbreaks several countries have taken exceptional measures to reinforce measles vaccination including Greece lowering the age of the second dose to the 2nd year of life, Denmark and Sweden facilitating vaccination of healthcare workers in addition to increased awareness communication campaigns.

Strengthening routine immunisation through facilitating access to vaccination, and mechanisms to identify people not or incompletely vaccinated are needed. Promoting and providing additional opportunities for immunisation through a variety of SIAs may be needed in countries with suboptimal coverage and/or pockets of susceptible individuals.

Vaccination coverage of at least 95% of the general population at national and subnational levels with two doses of measles containing vaccine is recommended and necessary to ensure that measles circulation is interrupted, and that introduction of measles cases does not result in secondary cases. This has not yet been achieved in all EU/EEA countries according to available vaccination coverage figures. The assessment of vaccination coverage and the

availability of data at subnational level would allow identification of geographical areas where targeted actions may be needed.

Strengthening and ensuring high-quality surveillance, including monitoring the changing epidemiology of measles, helps guide public health actions. All suspected cases need to be detected and investigated in order to break chains of transmission as soon as possible. Epidemiological investigations, including an assessment of the susceptibility of contacts, are needed to guide the control measures [18]. Adequate laboratory investigation is essential as data on viral genotype are needed to track transmission chains.

In light of the current outbreaks in several EU countries, individuals who have not been immunised with two doses of measles containing vaccine are at risk of being exposed and contracting measles. National immunisation recommendations need to be followed-up and implemented. As the vaccine is highly effective, healthcare providers should consider recommending vaccination for all eligible individuals who are not, or not fully immunised, in line with the national recommendations. Any encounter with the healthcare system should be used as an opportunity for a catch-up vaccination against measles as well as other vaccine-preventable diseases.

Travel can be a trigger to complete the vaccination status. EU/EEA citizens travelling to countries or regions experiencing outbreaks are advised to ensure their vaccination status is up to date before travel.

Given the current extent of measles circulation in the EU/EEA, the trend in the last years, and that vaccination coverage for the first and second dose is suboptimal, there is a high risk of continued measles transmission with mutual exportation and importation between EU/EEA Member States and third countries.

References

1. European Centre for Disease Prevention and Control. Health topics Measles [internet]. 2017 [cited 2017 Feb. 28]. Available from: <http://ecdc.europa.eu/en/healthtopics/measles/Pages/index.aspx>.
2. National Institute of Public Health Romania. Measles situation reports in Romania [internet]. 2018 [cited 2018 Mar. 9]. Weekly measles reports in Romania]. Available from: <http://www.cnsrbt.ro/index.php/informari-saptamanale/rujeola-1/>.
3. European Centre for Disease Prevention and Control. Communicable disease threats report : CDTR2018 9/02/2018. Available from: <https://ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-4-10-february-2018-week-6>.
4. European Centre for Disease Prevention and Control. Communicable disease threats report : CDTR Stockholm: ECDC; 2018 [updated 9/03/2018]. Available from: <https://ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-4-10-march-2018-week-10>.
5. World Health Organization. WHO/UNICEF estimates of national immunization coverage. Available from: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragemcv2.html.
6. Hellenic Center for Disease Control and Prevention. Measles surveillance reports [internet]. 2018 [cited 2018 Mar. 9]. Available from: http://www.keelpno.gr/el-%CE%B1%CF%81%CF%87%CE%B9%CE%BA%CE%B7/measles_highlight2017.aspx.
7. Santé Publique France. Measles outbreak in France. Update of surveillance data as of February 20, 2018. [internet]. 2018 [cited 2018 Mar. 9]. Available from: <http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Rougeole/Points-d-actualites/Epidemie-de-rougeole-en-France.-Actualisation-des-donnees-de-surveillance-au-20-fevrier-2018>.
8. National Health Service & Directorate General for Health Portugal. Measles outbreak - Update [internet]. 2018 [updated 2018 Mar. 19]. Available from: <https://www.dgs.pt/a-direccao-geral-da-saude/comunicados-e-despachos-do-director-geral/surto-de-sarampo-na-regiao-norte6.aspx>.
9. Czech television. Prague reports 23 cases of measles [internet]. 2018 [cited 2018 Mar. 2]. Available from: <http://www.ceskatelevize.cz/ct24/regiony/2407309-praha-hlasi-23-pripadu-spalnicek-onemocnelo-i-devet-deti-ktere-nenechali-rodice>.
10. Robert Koch Institute Germany. Epidemiological bulletin [internet]. 2018 [cited 2018 Mar. 7]. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/epid_bull_node.html.
11. Health Protection Surveillance Centre Ireland. Weekly Infectious Disease Report [internet]. 2018 [cited 2018 Mar. 7]. Available from: <http://www.hpsc.ie/notifiablediseases/weeklyidreports/>.
12. The Centre for Disease Prevention and Control of Latvia. Current information on the epidemiological situation with measles [internet]. 2018 [cited 2018 Mar. 9]. Available from: <https://spkc.gov.lv/lv/aktualitates/preses-relizes/get/nid/556>.

13. Norwegian Institute of Public Health. News. A new case of measles [internet]. 2018 [cited 2018 Mar. 2]. Available from: <https://www.fhi.no/nyheter/2018/nytt-tilfelle-av-meslinger/>.
14. The Public Health Agency of Sweden. Measles [internet]. 2018 [cited 2018 Feb. 24]. Available from: <https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/utbrotsarkiv/massling-goteborg-2017-/>.
15. Scientific Institute of Public Health of Belgium. FLASH Infectious Diseases - June 2017 - N ° 6 [internet]. 2017 [cited 2018 Mar. 13]. Available from: <https://www.wiv-isp.be/en>.
16. Regional Hygienic Station of Moravskoslez region and Ostrava Czech Republic. Measles, extinction of an outbreak in the Moravian-Silesian region [internet]. 2017 [cited 2018 Mar. 13]. Available from: <http://www.khsova.cz/homepage/detail-aktuality/12451>.
17. Italian National Center for Disease Prevention and Health Promotion. Measles in Italy: weekly bulletin. [internet]. 2018 [updated 13.12.2017]. Available from: <http://www.epicentro.iss.it/problemi/morbillo/infografica2017.asp>.
18. Hellenic Center for Disease Control and Prevention. Measles monthly surveillance report, Greece, 8 March 2018 [internet]. 2018 [cited 2018 Mar. 9]. Available from: <http://www.keelpno.gr/Portals/0/%CE%91%CF%81%CF%87%CE%B5%CE%AF%CE%B1/%CE%A0%CF%81%CE%BF%CE%BB%CE%B1%CE%BC%CE%B2%CE%AC%CE%BD%CE%BF%CE%BD%CF%84%CE%B1%CE%B9%20%CE%BC%CE%B5%20%CE%B5%CE%BC%CE%B2%CE%BF%CE%BB%CE%B9%CE%B1%CF%83%CE%BC%CF%8C/%CE%99%CE%BB%CE%B1%CF%81%CE%AC/2018/MHNIAIA%20%CE%95%CE%9A%CE%98%CE%95%CE%A3%CE%97%20%CE%99%CE%9B%CE%91%CE%A1%CE%91%CE%A3 8.3.2018.pdf>.
19. Sahlgrenska University Hospital Västra Götaland Region. Investigation after another case of measles [internet]. 2018 [cited 2018 Jan. 3]. Available from: <http://news.cision.com/se/sahlgrenska-universitetssjukhuset/r/smittsparning-efter-annu-ett-fall-av-massling,c2424160>.
20. National Health Service & Directorate General for Health Portugal. Measles in Portugal - North Region [internet]. 2018 [cited 2018 Mar. 17]. Available from: <https://www.dgs.pt/paginas-de-sistema/saude-de-a-a-z/sarampo1/boletim-epidemiologico.aspx>.
21. Statens Serum Institut. Expert Committee: MMR vaccination should also be free of charge for healthcare workers [internet]. 2018 [cited 2018 Mar. 14]. Available from: https://www.ssi.dk/Aktuelt/Nyheder/2018/2018_2_mfr_gratis.aspx.
22. Scandinavian Verification Committee for Measles and Rubella Elimination. Statement by the Scandinavian Verification Committee for Measles and Rubella Elimination, February 2018 [internet]. 2018 [cited 2018 Mar. 15]. Available from: https://www.ssi.dk/~media/Indhold/DK%20-%20dansk/Aktuelt/Nyheder/statement_svc_measles_2_2018.ashx.
23. Smittskydd Västra Götaland. Measles outbreak - Risk assessment and advice on vaccination [internet]. 2018 [cited 2018 Jan. 15]. Available from: <https://alfresco.vgregion.se/alfresco/service/vgr/storage/node/content/workspace/SpacesStore/312201df-d340-4897-8389-eff165241ae3/M%C3%A4sslingsutbrottet%20-%20Riskbed%C3%B6mning%20och%20r%C3%A5d%20om%20vaccination%202018-01-15.pdf?a=false&guest=true>.
24. European Centre for Disease Prevention and Control. Ongoing outbreak of measles in Romania, risk of spread and epidemiological situation in EU/EEA countries. Rapid risk assessment [Internet]. 2017. Available from: <http://ecdc.europa.eu/en/publications/Publications/27-02-2017-RRA-Measles-Romania,%20European%20Union%20countries.pdf>.
25. Italian Ministry of Health. Childhood and adolescent vaccinations - Vaccine coverage 2018 [cited 2018 Mar. 15]. Available from: http://www.salute.gov.it/portale/documentazione/p6_2_8_3_1.jsp?lingua=italiano&id=20.
26. Santé publique France. Measles weekly bulletin [14 March 2018]. Available from: <http://invs.santepubliquefrance.fr/fr/Dossiers-thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Rougeole/Points-d-actualites/Bulletin-epidemiologique-rougeole.-Donnees-de-surveillance-au-14-mars-2018>.
27. Hellenic Center for Disease Control and Prevention. Measles outbreak in Europe and Greece [internet]. 2018 [cited 2018 Mar. 9]. Available from: http://www.keelpno.gr/el-gr/apxkn/measles_highlight2017.aspx.
28. Papamichail D, Petraki I, Arkoudis C, Terzidis A, Smyrnakis E, Benos A, et al. Low vaccination coverage of Greek Roma children amid economic crisis: national survey using stratified cluster sampling. Eur J Public Health. 2017 Apr 1;27(2):318-24.
29. Public Health Centre of the Ministry of Health of Ukraine. The situation with measles stabilizes. A new batch of vaccines is already in the regions. [internet]. 2018 [cited 2018 Mar. 7]. Available from: <https://phc.org.ua/news/show/situaciya-iz-zahvoryuvanistyu-na-kir-stabilizujetsya-nova-partiya-vakcin-uzhe-v-regionah>.
30. Institute of Public Health of Serbia. The current epidemiological situation of measles in the Republic of Serbia [internet]. 2018 [cited 2018 Mar. 13]. Available from: <http://www.batut.org.rs/index.php?content=1629>.

- 13